Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

NCT03758417 is registered in ClinicalTrials.gov with Nanjing Legend Biotech Co. as lead sponsor.

NCT NCT03758417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03758417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Nanjing Legend Biotech Co.
Phase
Phase 2
Overall status
Terminated
Start date
January 23, 2019
Completion date
October 20, 2025
Enrollment
123 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma